Company

Fusion Antibodies plc

Headquarters: Belfast, United Kingdom

Employees: 55

LSE: FAB +4.07%

Market Cap

£9.0 Million

GBP as of Jan. 1, 2025

US$11.2 Million

Market Cap History

Fusion Antibodies plc market capitalization over time

Evolution of Fusion Antibodies plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Fusion Antibodies plc

Detailed Description

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Sept. 30, 2023
Revenue TTM £1.6 M
EBITDA £-2,799,000
Gross Profit TTM £574,000
Profit Margin -179.67%
Operating Margin -262.29%
Quarterly Revenue Growth -71.00%
Financial Reports & Statistics

Stocks & Indices

Fusion Antibodies plc has the following listings and related stock indices.


Stock: LSE: FAB wb_incandescent

Details

Headquarters:

1 Springbank Road

Springbank Industrial Estate Dunmurry

Belfast, BT17 0QL

United Kingdom

Phone: 44 28 9043 2800

Fax: 44 28 9002 0446